Urinary metabolomics analysis of patients with renal tubular dysfunction after PCI surgery.

PURPOSE

Differences in metabolic profiles were used to search for urinary metabolic markers in patients with tubular dysfunction after percutaneous coronary intervention (PCI).

METHODS

In this study, 50 patients with renal tubule dysfunction 6 h after PCI were collected and urine samples before PCI were used as control group and 6 h after PCI were used as observation group. The urine samples were processed by high-speed centrifugation, filtered by microporous membrane, and the superclear was obtained for LC-MS detection and analysis, and their metabolic profiles and related data were obtained.

RESULTS

Compared with the control group, α1-MG, NAG and Cys-C in the urine of the observation group were significantly increased, and the difference was statistically significant (P < 0.05). After the urine samples were processed by LC-MS technology, SIMCA realized the visual visualization of the score plots of PCA, OPLS-DA and other models, and then verified by statistical methods, it was found that there were different metabolites in the urine of patients before and after PCI. The HMDB database was used to search for differential metabolites and 16 different metabolites such as L-ornithine, oleic acid amide, D-histidine, p-hydroxyphenyllactic acid, acetylmethionine, N-(2-furanyl) glycine, cholesterol laurate, cholic acid, 1-methylguanine, L-hydrochloric acid, homovanillic acid, alpha-keto-isocaproic acid, 3-β-hydroxy-D5-cholenoic acid, adenine, palmitic acid, pentadecanoic acid. Pathway Analysis in MetaboAnalyst5.0 was used to analyze the metabolic pathways of 16 different metabolites. Finally, a total of 11 metabolic pathways were matched. Finally, we believe that the biosynthetic pathway of arginine and the metabolic pathway of alanine, aspartate and glutamate are most relevant to tubular dysfunction after percutaneous coronary intervention (PCI).

CONCLUSION

In this study, LC-MS technology was used to analyze urine samples from CIN patients and patients with coronary heart disease before and after PCI and a total of 16 different metabolites were screened out, which may serve as potential biomarkers to help diagnose renal tubular dysfunction. There are 11 metabolic pathways in the body involved in the occurrence and development of renal tubular dysfunction after angiography and the biosynthesis pathway of arginine and the metabolic pathway of alanine, aspartate and glutamate may play the most important role in the occurrence and development of renal tubular dysfunction.